肝门部胆管癌

预约门诊

生存率

肝门部胆管癌又称肝门周围胆管癌或克拉茨金瘤，是一种侵袭性癌症，常常在没有任何症状的情况下生长，直至阻塞胆管。由于患者多是在疾病已经扩散后才被确诊，因此总生存率一直较低。

术后

通过手术完全切除癌症（也就是常说的 R0 切除），是能带来长期生存机会的唯一治疗方法。如果在切除组织的边缘发现了癌细胞，则被称为 R1 或 R2 切除，生存率会降低。如果癌症已经扩散到淋巴结或血管，生存率也会降低。

如果癌症部位无法切除

如果无法进行手术，则治疗侧重于缓解症状和减缓癌症生长。预计这些疗法无法治愈癌症，但可以帮助改善生活质量并延长生存期。

治疗方法通常包括化疗或免疫疗法。通常首先考虑化疗，能否进行免疫疗法则取决于肿瘤的遗传特征。大多数患者即使接受治疗，也只能存活 6 到 12 个月。

肝移植后

有些患者的小型局部肿瘤无法切除，在专科中心进行肝移植或许是一个选项。这些患者的癌症尚未扩散到淋巴结或远处器官，而且对移植前的放化疗反应良好。部分患者接受移植后的结果可能好于手术，例如同时患有原发性硬化性胆管炎者。

申请预约
分期医生与科室
Jan. 20, 2026

Living with 肝门部胆管癌?

Connect with others like you for support and answers to your questions in the Sarcoma support group on Mayo Clinic Connect, a patient community.

Sarcoma Discussions

jonezzi
Myxofibrosarcoma: What treatments did you have?

159 Replies Thu, Jul 30, 2026

Colleen Young, Connect Director
Diagnosed with sarcoma? Let's share

1077 Replies Wed, Jul 29, 2026

ricosoriano
Malignant Peripheral Nerve Sheath Tumor

14 Replies Tue, Jul 28, 2026

See more discussions
  1. Cameron JL, et al., eds. Management of intrahepatic, perihilar, and distal extrahepatic cholangiocarcinoma. In: Current Surgical Therapy. 14th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed Nov. 12, 2024.
  2. Feldman M, et al., eds. Tumors of the bile ducts, gallbladder, and ampulla. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Nov. 12, 2024.
  3. Biliary tract cancers. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517. Accessed Nov. 12, 2024.
  4. Bile duct cancer (cholangiocarcinoma) treatment — Health professional version (PDQ). National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 12, 2024.
  5. Soares KC, et al. The Landmark Series: Hilar cholangiocarcinoma. Annals of Surgical Oncology. 2021; doi:10.1245/s10434-021-09871-6.
  6. Lowe RC, et al. Clinical manifestations and diagnosis of cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  7. Anderson CD. Surgical resection of localized cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  8. Anderson CD, et al. Adjuvant and neoadjuvant therapy for localized resectable cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  9. Anderson CD, et al. Treatment of locally advanced unresectable nonmetastatic cholangiocarcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 12, 2024.
  10. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 12, 2024.
  11. Suarez-Munoz MA, et al. Risk factors and classifications of hilar cholangiocarcinoma. World Journal of Gastrointestinal Oncology. 2013; doi:10.4251/wjgo.v5.i7.132.
  12. Soares KC, et al. Hilar cholangiocarcinoma: Diagnosis, treatment options, and management. Hepatobiliary Surgery and Nutrition. 2014; doi:10.3978/j.issn.2304-3881.2014.02.05.
  13. MRCP (MR cholangiopancreatography). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/mrcp. Accessed Nov. 18, 2024.
  14. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Dec. 5, 2024.
  15. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Feb. 6, 2025.
  16. Breuer E, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Annals of Surgery. 2022; doi:10.1097/SLA.0000000000005641.
  17. Medical review (expert opinion). Mayo Clinic. Nov. 11, 2025.

相关

相关医疗程序

产品与服务

肝门部胆管癌